Copyright
©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Dec 7, 2012; 18(45): 6577-6586
Published online Dec 7, 2012. doi: 10.3748/wjg.v18.i45.6577
Published online Dec 7, 2012. doi: 10.3748/wjg.v18.i45.6577
Figure 5 Survival analysis of gastric cancer patients.
Three year survival of human epidermal growth factor receptor 2 (HER2)-positive vs HER2-negative, 29.1 mo vs 59.4 mo; Phosphatidylinositol 3-kinase, catalytic, alpha polypeptide (PIK3CA) mutation vs wild type, 63.7 mo vs 56.3 mo; Epstein-Barr virus (EBV)-positive vs EBV-negative, 51.3 mo vs 57.6 mo; And phospho Akt (pAkt)-positive vs pAkt-negative, 50.7 mo vs 64.8 mo. Five year survival of pAkt-positive vs pAkt-negative cases, 35.5 mo vs 58.1 mo.
- Citation: Sukawa Y, Yamamoto H, Nosho K, Kunimoto H, Suzuki H, Adachi Y, Nakazawa M, Nobuoka T, Kawayama M, Mikami M, Matsuno T, Hasegawa T, Hirata K, Imai K, Shinomura Y. Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer. World J Gastroenterol 2012; 18(45): 6577-6586
- URL: https://www.wjgnet.com/1007-9327/full/v18/i45/6577.htm
- DOI: https://dx.doi.org/10.3748/wjg.v18.i45.6577